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1. Introduction 
Cardiac arrhythmia is a major mortality cause in both acquired and inherited 
cardiomyopathy, accounting for more than 750.000 deaths per year (~ 0.1% of total recorded 
deaths) in Europe and the USA (Priori SG, 2002). The 2008 WHO rapport has foreseen that 
cardiovascular disease will be the world leading death cause in the near future, surpassing 
infectious diseases. 
Some of these cardiac diseases are acquired as cardiac hypertrophy, which develops as an 
adaptation of the heart to diseases that challenge the heart work chronically. Cardiac 
hypertrophy often degenerates in heart failure (HF), the final outcome of most 
cardiovascular diseases. Chronic HF prevalence is increasing in western countries, with only 
25% of men and 38% of women surviving 5 years after the onset of clinical signs. Quality of 
life is hampered by the reduced pump function, which can also lead to death. However, half 
of deceases in HF patients are sudden due to cardiac arrhythmia. During cardiac pathology, 
altered activity of the cardiac, type 2, ryanodine receptor (RyR2) may generate arrhythmia 
and sudden death. This risk is high in HF where there is a profound remodeling of Ca2+ 
cycling, and alterations in transmembrane Ca2+ influx, Ca2+ release or/and sarcoplasmic 
reticulum (SR) Ca2+-load underlie systolic dysfunction (Gómez et al., 1997; Bénitah JP, 2002). 
Thus, when dealing with HF and poor cardiac outcomes, it is a need to better understand 
the mechanisms of cardiac arrhythmia in order to efficiently treat these patients. However, a 
large number of inherited arrhythmogenic syndromes that cause sudden death have been 
characterised. Some are associated with structural heart disease, such as familial 
hypertrophic cardiomyopathy and arrythmogenic right ventricular cardiomyopathy type 2 
(ARVD2). Others do not produce structural heart disease and so are difficult to detect. Most 
of these cardiomyopathies are due to mutations in plasmalemmal cardiac ion channels, 
mainly the Na+ channel and several K+ channels (Lehnart et al., 2007). These mutations 
promote arrhythmogenesis by altering the action potential (AP) duration, which therefore 
may enhance the propensity of arrhythmic activity via the development of early after 
depolarizations (EADs). However, the recent finding of mutations in the Ca2+ release 
channel (RyR2) associated with catecholaminergic polymorphic ventricular tachycardia 
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(CPVT) and ARVD2 has opened a new view of arrhythmogenesis, evidencing that 
alterations in intracellular Ca2+ cycling can generate arrhythmia (Priori SG, 2001). CPVT is a 
familial arrhythmogenic disorder characterised by syncopal events and Sudden Cardiac 
Death occurring in children and young adults during physical stress or emotion in the 
absence of structural heart disease. In addition to the severe phenotype, CPVT exhibits a 
cumulative mortality of 30 – 50% by 35 years. To date, more than 145 RyR2 mutations have 
been identified as causative of CPVT in affected individuals, which appear clustered in 3 
“hot spots”. Some of these mutations have been investigated in several in vitro systems 
(lipid bilayers, HEK293 cells, HL1-cardiomyocytes), suggesting that CPVT-linked RyR2 
mutations produced an increase of the RyR2 activity, termed as RyR2 Ca2+ leakage, under 
beta-adrenergic stimulation (Lehnart et al., 2004). This abnormal SR Ca2+ release during 
diastole would activate the Na+-Ca2+ exchanger (NCX) to extrude Ca2+ out of the cell. Since 
NCX is electrogenic, a net inward current is generated for each Ca2+ ion extruded, which 
could develop delayed after depolarizations (DADs) and evoke triggered activity if they 
reach threshold. This abnormality may promote arrhythmogenesis in CPVT patients, where 
the increased RyR2 activity may generate DADs through the activation of NCX (Nakajima et 
al., 1997). This mechanism is interestingly very similar to the one that has been suggested in 
HF, where chronic hyperadrenergic state generates an inadequate diastolic Ca2+ release (Ca2+ 
leak) and SR Ca2+ depletion, leading to a decreased myocardial contractility. Recently, Priori’s 
laboratory has developed a knock-in mouse model carrying a highly penetrant R4496C 
mutation in the RyR2 (equivalent to the human R4497C mutation), identified in an Italian 
family with CPVT. Previous reports have shown that these mice developed bidirectional and 
polymorphic ventricular tachycardia under the injection of isoproterenol (β-adrenergic 
agonist) and caffeine (Cerrone et al., 2005). Interestingly, the presence of DADs was detected 
after high pacing rates and under the application of isoproterenol, in isolated ventricular 
myocytes (Liu et al., 2006). Our laboratory has also performed experiments using this mouse 
model and, in addition to other findings, we observed abnormal cytosolic Ca2+ release and 
spontaneous triggering activity, in ventricular myocytes paced at high rates or treated with 
isoproterenol (Fernandez-Velasco M, et al 2009). In this chapter, we will review the latest 
knowledge on the role of intracellular Ca2+ on cardiac arrhythmia in acquired and inherited 
diseases, paying special attention to the molecular and cellular mechanisms of the disease. 
2. Involvement of RyR in cardiac arrhythmias 
The cardiac RyR is the major Ca2+ release channel in the ventricle and it is central in activating 
contraction by the mechanism of Ca2+ -induced Ca2+ release during the excitation-contraction 
process. It is located in the membrane of the SR, mainly in the junctional SR, facing the L-type 
Ca2+ channels located in the membrane invaginations termed trasverse tubules. During cardiac 
excitation-contraction coupling (ECC), the membrane depolarization during the AP activates 
Ca2+ influx via sarcolemmal L-type Ca2+ channels, providing enough Ca2+ to activate the RyR 
(Fabiato, 1983; Bers, 2002). By this mechanism, the initial Ca2+ signal is greatly amplified, then 
providing enough Ca2+ for contraction. Relaxation occurs when calcium is removed from 
cytosol, mainly by NCX and SR Ca2+-ATPase (SERCA). The sarcolemmal Ca2+ ATPase, 
different from SERCA, can also extrude some Ca2+. However, its contribution appears to be 
minor (about 3% of total Ca2+ removal) and its physiological significance has yet to be 
determined. For equilibrium to occur, the amount of Ca2+ extruded through the NCX should 
be equivalent to the amount of Ca2+ entering the cell through DHPRs, and the amount of Ca2+ 
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transported by SERCA should be equivalent to Ca2+ released by the SR. For each Ca2+ 
extruded, the NCX enters 3 Na+, generating thus an inward current. In cases of Ca2+ overload, 
spontaneous SR Ca2+ release through RyRs produces Ca2+ waves, activating transient inward 
currents (Iti), (Berlin et al., 1989) which if they reach threshold may trigger an action potential 
(triggered activity). The NCX is centrally involved in this current (Venetucci et al., 2007). 
Triggered activity-derived arrhythmias are produced by after depolarizations that can occur 
early during the repolarization phase of the action potential (early after depolarization, EAD) 
or late, after completion of the repolarization phase (delayed after depolarization, DAD) 
(Figure 1). When either type of after depolarization is large enough to reach the threshold 
potential for activation of a regenerative inward current, a new AP is generated, which is 
named as triggered activity. 
 
Fig. 1. Example of an early after depolarization (EAD) and delayed after depolarization 
(DAD) leading to triggered activity. 
3. Involvement of RyR in cardiac arrhythmias in the hypertrophied and failing 
heart 
Half of the deaths in heart failure patients are due to sudden death and cardiac hypertrophy 
has also an elevated risk of sudden death, which may arise as a consequence of ventricular 
arrhythmia. The ventricular cardiomyocytes of these hearts are prolonged, which favors the 
occurrence of early EADs. EADs are believed to be dependent on the L-type Ca2+ channel. 
DADs are common of Ca2+ overloaded cells, which is uncommon in heart failure. However, 
the RyR activity is altered, which may favor DADs. Several modifications that happen in the 
RyR of the failing hearts have been shown to promote diastolic Ca2+ leak and be 
arrhythmogenic. These modulations include phosphorylation (PKA and/or CaMKII), 
oxidation, decreased nitrosylation, lost of its accessory protein FKBP12.6 (calstabin 2) and 
unzipping. However, the RyR leakiness would not be enough to provoke arrhythmia, 
because it should be compensated by the reduction in SR Ca2+ load (Venetucci et al., 2008). 
Hyperphosphorylation of RyR by PKA was found in humans at end stage heart failure and 
different models of heart failure (Marx et al., 2000; Reiken et al., 2003) and related to sudden 
death (Marks, 2001), although controversed (Jiang et al., 2002). RyR phosphorylation 
increases activity of RyR, making RyR leaky and thus favoring arrhythmia. The RyR is also 
hyperphosphorylated at the CaMKII site (Ai et al., 2005) during heart failure, which may be 
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involved in the propensity to arrhythmias. In this sense, CaMKII blockade repressed the 
spontaneous Ca2+ waves in heart failure cardiomyocytes (Curran et al.). 
RyR phosphorylation in heart failure has been suggested to unbind the RyR from its 
regulatory protein, the FKBP12.6 (Marx et al., 2000). While the direct correlation with 
phosphorylation is a matter of debate (Maier et al., 2003; Blayney et al., 2010), the cardiac 
expression of FKBP12.6 is reduced in heart failure, causing diastolic Ca2+ leak that may 
result in higher propensity of DADs and consequent triggered arrhythmias (Shou et al., 
1998; Yano et al., 2000; Reiken et al., 2001; Xin et al., 2002; Wehrens et al., 2004; Ai et al., 2005; 
Wehrens et al., 2005; Yano et al., 2005; Huang et al., 2006; Yano et al., 2006; Gomez et al., 2009). 
Supporting the role of FKBP12.6 in arrhythmia, stabilizing FKBP12.6 binding to RyR by 
FKBP12.6 overexpression prevents triggered arrhythmias in normal hearts, probably by 
reducing diastolic SR Ca2+ leakage (Gellen et al., 2008). Conversely, FKBP12.6 knockouts 
exhibited exercise induced ventricular arrhythmia (Wehrens et al., 2003). 
Other alterations during heart failure may affect RyR function. In this sense, RyR oxidation in 
a canine model of sudden death are involved in arrythmogenic [Ca2+]i transients alternans 
(Belevych et al., 2009). Moreover, the increase in xantine oxidase activity also reduces the level 
of S-nytrosilation. The RyR hyponitrosylation has also been involved in the Ca2+ leak from SR 
in experimental heart failure (Gonzalez et al., 2010). This alteration might contribute to the 
arrhythmogenesis in heart failure. In this sense, it has been shown that NOS1-/- mice show 
RyR hyponitrosylation with consequent SR Ca2+ leak and an arrhythmic phenotype, without 
altering the FKBP12.6 stoichiometry (Gonzalez et al., 2007). Consistent with these findings, 
NOS1 overexpression protected the mice in a model of heart failure by preserving Ca2+ cycling 
(Loyer et al., 2008). However, others have found that RyR is hypernitrosilated in a model of 
muscular dystrophy, where arrhythmias are frequent, suggesting that hypernytrosilated RyR 
is leaky. It should be noted that in this model the binding to FKBP12.6 was also decreased 
(Fauconnier et al., 2010), which may account for the RyR leakiness. 
The N and central domains of the RyR interact with each other in a process called “zipping”, 
which stabilizes the channel in its closed state (Ikemoto & Yamamoto, 2002). In heart failure, 
the RyR is unzipped favoring its phosphorylation and unbinding to FKBP12.6 (Oda et al., 
2005). 
Besides these direct alterations of the RyR, this channel may be “sensitized” in some 
conditions by an increase in the local [Ca2+] around it, from either side of the SR membrane. 
In this sense, the increase in the IP3R expression in the junctional SR during heart failure 
might, under certain circumstances, locally increase the [Ca2+]i in the neighboring RyRs and 
facilitate Ca2+ waves propagation (Harzheim et al., 2009). Increasing the [Ca2+]i in the 
luminal side, as by an increase in SERCA activity, might also sensitize the RyR and 
participate in Ca2+ waves formation (Keller et al., 2007) although SERCA activity is thought 
to be depressed in heart failure. 
4. Involvement of RyR in inherited cardiac arrhythmias 
4.1 Catecholaminergic polymorphic ventricular tachycardia 
CPVT is a rare arrhythmogenic disease characterized by exercise or stress induced 
ventricular tachyarrhythmia, syncope, or sudden death that appear in individuals with 
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structural normal hearts (Leenhardt et al., 1995; Coumel, 1997; Priori et al., 2002). Because 
the electrocardiogram (ECG) of CPVT patients is unremarkable under basal conditions, 
the diagnosis is established in symptoms and the detection of stress-induced arrhythmias 
during exercise test or Holter recording. Although some CPVT patients develop 
polymorphic ventricular tachycardia (VT), the bidirectional VT is considered the 
diagnostic marker of CPVT (Priori et al., 2002). Interestingly, bidirectional VT occurs 
during digitalis intoxication, where the Na+/K+ ATPase pump is inhibited, increasing the 
intracellular Na+ concentration that in turn, by NCX induces an intracellular Ca2+ 
overload, triggering arrhythmogenic DADs (Rosen & Danilo, 1980). Thus, it was 
reasonable to postulate that bidirectional VT in CPVT patients can be due to changes in 
the intracellular calcium handling. Indeed, several reports have associated CPVT with 
mutations in genes encoding key-proteins involved in the control of intracellular calcium 
handling, such as RyR2 and calsequestrin (CASQ2), causative of CPVT1 and CPVT2, 
respectively (Lahat et al., 2001a; Priori et al., 2002). 
4.2 RyR2 mutations in CPVT 
The gene encoding RyR2 (chromosome 1q42.1–43) consists of 105 exons, which encodes 4967 
amino acids (∼560 kDa) and it is one of the largest and most intricate in the human genome. 
The RyR2 is a homotetramer with hydrophobic segments of the four identical subunits 
forming a central Ca2+ pore (Wagenknecht, 1989). Currently more than 145 RyR2 mutations 
have been reported as causative of CPVT, and they continue growing since the first 
mutations was reported a decade ago (Priori SG, 2001) – an updated database is shown in 
the ‘Gene connection for the heart’ website (http://www.fsm.it/cardmoc/). Some of these 
RyR2 mutations have been identified in patient groups screened for Long QT syndrome 
(Tester DJ, 2005), and ARVD2 (Tiso et al., 2001). CPVT-related arrhythmias are by far 
reproduced during an exercise stress test, by isoproterenol infusion, or by other forms of 
adrenergic stimulation (Sumitomo et al., 2003; Vyas et al., 2006). A genetic screening of RyR2 
is necessary to verify the disease in patients suspicious of CPVT1, although this strategy is 
time consuming and expensive. However, screening for RyR2 mutations could be simplified 
due to the circumstance that CPVT mutations used to cluster in certain exons, and a tiered 
scan of these exons can be used to lower the cost (Medeiros-Domingo A, 2009). RyR2 
mutations linked to CPVT are clustered into 3 discrete protein regions or “hot spots”: N-
terminus (32% ), central domain (30% ) and C-terminus (38%) (Yano et al., 2006; George CH, 
2007). Similar mutation clustering is observed in the RYR1 gene, which encodes the skeletal 
muscle RyR1 and is linked to malignant hyperthermia and central core disease (Dirksen, 
2002). The N-terminus (also called domain I: amino acids 77-466) is a domain particularly 
susceptible to conformational change. It contains the cytoplasmic loop, which it is 
postulated that interacts with the central domain (zipping) stabilizing RyR2 activity during 
diastole (Yamamoto T, 2000). The central domain (domain II: amino acids 2246-2534) 
contains an FKBP12.6 binding domain (1636–1937) and it is supposed to interact with the N-
terminus domain (zipping-unzipping). The C-terminus domain (domain III: amino acids 
3778-4201 and domain IV: amino acids 4497 to 4959) contains the transmembrane regions of 
the Ca2+ channel and an hydrophobic region which it is postulated to transduce cytoplasmic 
events to regulate the Ca2+ pore forming domain (George CH., 2006). Only a small number 
of mutations are located in regions of RyR2 outside these portions. By contrast to other 
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channelopathies, most of the RyR2 mutations described in CPVT are single nucleotide 
replacements (“point mutations”) leading to an amino acid substitution. 
4.3 Functional alterations of CPVT related mutations in the RyR 
Although the phenotypic manifestation of CPVT is usually the stress-induced development 
of bidirectional or polymorphic ventricular tachycardia, patient symptoms are 
heterogeneous, presenting in some cases high variability among affected subjects within the 
same family (d’Amati & King, 2005). However in other cases, patients with point mutations 
located in the same RyR2 cluster present similar CPVT symptoms, probably because they 
affect RyR2 function in a common way. To improve the current knowledge of RyR2 
complexity and to provide an adequate treatment to CPVT patients, it is necessary to study 
the molecular mechanisms of all sudden cardiac death (SCD)-linked mutations screened. A 
number of studies on them have been undertaken. Most of them have been analyzed in 
heterologous systems, but some transgenic mice have been constructed, allowing the 
exploration of the cardiac function. 
CPVT-linked mutations have been expressed in various heterologous systems (lipid bilayer, 
HEK293 cells, HL1-cardiomyocytes). Specifically, HEK293 cells (human embryonic kidney 
cell line) have been widely used as an expression system. This cell line presents some weak 
points such as it lacks ECC proteins and the contractile machinery that characterizes heart 
cells. However, it presents several advantages: 1) it is easy to transfect using conventional 
methods and, 2) as it does not express native RyR, they cannot interfere with expressed 
constructs. 
Some human N-terminus mutations (R176Q/T2504M and L433P), central domain mutations 
(S2246L and R2474S), and C-terminus mutations (N4104K, Q4201R, R4496C, I4867M and 
N4895D) have been explored using HEK293 cells. These RyR2 mutations showed an 
increased frequency of spontaneous Ca2+ oscillations and a reduced Ca2+ store content, thus 
displaying gain-of-function (Jiang et al., 2004; Jiang D, 2005). In addition, most mutated 
RyR2 incorporated into lipid bilayers displayed an increased sensitivity to luminal Ca2+, 
although the two N-terminus mutants were 10-fold less sensitive than the others (Jiang D, 
2005). However, some RyR2 mutants displayed an increased sensitivity to cytosolic Ca2+ and 
caffeine. This is the case for S2246L, N4104K and R4497C mutations expressed in HEK293 
cells or HL-1 cells, where it was also shown a gain-of-function RyR2 activity, while there 
was no change in SR Ca2+ load (George CH., 2006). In some cases, differences in RyR2 
mutants’ response to agonists are closely dependent on the mutational locus. This may be 
the case of a report from Thomas and coworkers, who have observed marked differences in 
caffeine-dependent Ca2+ release in N-terminal and central domain ARVD2-linked RyR2 
mutations (L433P, N2386I and R176Q/T2504M) (Thomas et al., 2004; George CH & .2005). 
Interestingly, one of these 3 mutations (L433P) was not associated with gain-of-function, but 
rather with loss-of-function (George CH & . 2005). 
It is of note that the characterization of RyR2 mutations according to the mutational locus 
may be of large interest because this permits to design a model which integrates domain-
specific arrhythmogenic mechanisms. The result model could extrapolate how new 
mutations may affect RyR2 function, allowing for a common therapy that restores channel 
activity. Table 1 shows a classification of SCD-linked mutations characterized so far. 
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Location in 
RyR2 
Mutation Disease Characterization System 
RyR2 
defect 
N-Terminal R176Q ARVD / SUO
Enhanced SOICR increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2005); R176Q/T2504M 
increase caffeine-dependent 
sensibility to cytosolic Ca2+ 
(Thomas, 2005); myocytes elicited 
oscillatory Ca2+ signals under -
adrenergic stimulation. 
(Kannankeril et al., 2006) 
HEK293 
Lipid bilayers 
Knock-in 
mice 
Gain-of-
function 
N-Terminal E189D CPVT 
Increases the propensity of SOICR 
and enhance caffeine sensitivity. 
(Jiang D, 2010) 
HEK293 
 
Gain-of-
function 
N-Terminal G230C CPVT 
Increased sensibility to cytosolic 
Ca2+, decreased FKBP-12.6 
binding (Meli, 2011) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
N-Terminal L433P  ARVD 
Enhanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2005) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
      
Decrease caffeine-dependent, 
sensibility to cytosolic Ca2+ 
(Thomas, 2005), desensitized 
response to caffeine (Thomas et 
al., 2004) 
HEK293 
 
Loss-of-
function 
Cytoplasmic 
loop 
G1885E ARVC 
Enhanced SOICR, reduced RyR2 
activity in G1885E/G1886S 
double mutant. (Koop, 2008) 
HEK293 
 
Gain-of-
function 
Cytoplasmic 
loop 
G1886S ARVC 
Enhanced SOICR, reduced RyR2 
activity in G1885E/G1886S 
double mutant. (Koop, 2008) 
HEK293 
 
Gain-of-
function 
Cytoplasmic 
loop 
S2246L CPVT/IVF 
PKA-dependent increased RyR2 
activity (Wehrens et al., 2003); 
PKA and caffeine-dependent 
increased RyR2 activity (George 
et al., 2003);abnormal domain 
interaction (George CH., 
2006);enhanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
et al., 2004) 
HEK293 
Lipid bilayers 
CHO 
HL-1 
Gain-of-
function 
Cytoplasmic 
loop 
R2267H CPVT 
PKA-dependent increased 
sensitivity to cytosolic Ca2+ 
(Tester, 2007) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
FKBP binding 
dom. 
P2328S  CPVT 
Decreased FKBP-12.6 binding, 
PKA-dependent increased RyR2 
activity (Lehnart et al., 2004) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
FKBP binding 
dom. 
N2386I  ARVD 
Increase caffeine-dependent, 
sensibility to low cytosolic Ca2+ 
(Thomas, 2005) 
HEK293 
 
Gain-of-
function 
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Location in 
RyR2 
Mutation Disease Characterization System 
RyR2 
defect 
FKBP binding 
dom 
R2474S  CPVT 
Enhanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2004); (Wehrens et al., 2003); 
abnormal zipping-unzipping 
interaction, increase caffeine-
dependent, sensibility to 
cytosolic Ca2+ (Yang, 2006); 
increased frequency of 
spontaneous Ca2+ transients and 
increased sensitivity to luminal 
Ca2+ mediated by defective 
interdomain interaction. 
(Uchinoumi et al., 1998) 
HEK293 
Lipid bilayers 
Permeabilize
d myocytes 
from rats 
Knock-in 
mice 
Gain-of-
function 
FKBP binding 
dom. 
T2504M ARVD 
R176Q/T2504M increase 
caffeine-dependent sensibility to 
cytosolic Ca2+ (Thomas, 2005); 
R176Q/T2504M enhance SOICR 
and increase sensitivity to 
luminal Ca2+ (Jiang D, 2005) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
TM Domain N4104K  CPVT 
PKA and caffeine-dependent 
increased RyR2 activity (George et 
al., 2003); abnormal I domain 
interaction (George CH., 2006); 
enhanced SOICR (Jiang D, 2005); 
increased sensitivity to luminal 
Ca2+ (Jiang D, 2004) 
HEK293 
Lipid bilayers 
CHO 
HL-1 
Gain-of-
function 
TM Domain  Q4201R CPVT 
Ehanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2005); decreased FKBP-12.6 
binding, PKA-dependent 
increased RyR2 activity (Lehnart 
et al., 2004) 
HEK293 
Lipid bilayers 
 
Gain-of-
function 
TM Domain  R4497C CPVT 
PKA-dependent increased RyR2 
activity (Wehrens et al., 2003); 
PKA and caffeine-dependent 
increased RyR2 activity (George 
et al., 2003); abnormal I domain 
interaction (Uchinoumi et al., 
1998); enhanced SOICR (Jiang D, 
2005); increased sensitivity to 
luminal Ca2+ (Jiang et al., 2004); 
increased sensitivity to low 
cytosolic Ca2+, caffeine-
dependent increased RyR2 (Jiang 
et al., 2002); Increased sensitivity 
to cytosolic Ca2+ , triggering 
activity in ventricular myocytes 
in presence of high pacing rate 
and isoproterenol. (Fernandez-
Velasco et al., 2009) 
HEK-293 
Lipid bilayer 
CHO 
HL-1 
Knock-in ce 
Gain-of-
function 
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Location in 
RyR2 
Mutation Disease Characterization System 
RyR2 
defect 
TM Domain V4653F  CPVT 
Decreased FKBP-12.6 binding, 
PKA-dependent increased RyR2 
activity (Lehnart et al., 2004); 
Increased sensitivity to cytosolic 
Ca2+ (Tester, 2007)
HEK293 
Lipid bilayers 
 
gain-of-
function 
TM Domain A4860G  IVF 
Reduced sensitivity to luminal 
Ca2+, reduced SOICR activity 
(Jiang D, 2007)
HEK293
Lipid bilayers 
Loss-of-
function 
C-term I4867M CPVT 
Enhanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2005)
HEK293
Lipid bilayers 
Gain-of-
function 
C-term  N4895D CPVT 
Enhanced SOICR, increased 
sensitivity to luminal Ca2+ (Jiang 
D, 2004)
HEK293 
Lipid bilayers 
Gain-of-
function 
Table 1. RyR2 mutations linked to SCD disease characterized so far. Amino acid mutations 
are listed in order according to the mutational locus. CPVT=Catecholaminergic Polymorphic 
Ventricular Tachycardia; ARVD=Arrhythmogenic Right Ventricular Dysplasia; IVF = 
Idiopathic Ventricular Fibrillation induced by emotion or exercise. TM = Transmembrane 
domain; SUO = syncope of unknown origin;; SOICR = Store-operated induced- Ca2+ 
release; HEK293 = Human embrionic kidney cell line; CHO = Chinese hamster ovary cell 
line; HL-1 = cardiac myocyte cell line. 
Because animal’s models can contribute to the better understanding of the molecular 
mechanisms involved in the arrhythmogenic disease, transgenic mice models that harbor 
some of the most important RyR2 mutations observed in CPVT patients were developed 
(Uchinoumi et al., ; Cerrone et al., 2005; Kannankeril et al., 2006). 
These animals mimic several of the abnormal electrical events observed in CPVT subjects. 
Indeed, delayed after depolarization (DADs) and triggered activity have been detected in 
knock-in models of CPVT (Liu et al., 2006). It has been proven by different authors that 
cardiac myocytes isolated from CPVT models show abnormal diastolic Ca2+ release (Ca2+ 
leak) as Ca2+ sparks and/or Ca2+ waves, which may conduce to arrhythmia by DADs 
(Uchinoumi et al., ; Kannankeril et al., 2006; Fernandez-Velasco et al., 2009). 
One mice model that harbor RyR2 (R2474S) mutation leading to CPVT upon exercise and β-
adrenergic stimulation was developed by Lehnart et al., (Lehnart et al., 2008). 
Cardiomyocytes isolated from R2474S mice exhibited abnormal calcium diastolic leak, 
calcium waves, APs and inward currents upon isoproterenol treatment. Tonic-clonic 
seizures were identified in these mice, consistent with the neurological dysfunction 
including epilepic seizures detected in CPVT patients (Leenhardt et al., 1995; Postma et al., 
2005; Lehnart et al., 2008). 
Another mechanism by which mutation can alter the calcium handling in CPVT is the 
disruption of protein-protein interaction. In this context, Wehrens et al., established a direct 
link between FKBP12.6 and CPVT process (Wehrens et al., 2004). FKBP12.6 (calstabin 2) is an 
accessory subunit that maintains the RyR2 closed, avoiding calcium leak during diastole. 
Wehrens et al., proposed that CPVT mutations induce the dissociation of FKBP12.6 from 
RyR2 upon β-adrenergic stimulation. Therefore, this effect induces a deregulation of the  
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RyR2 gating, increasing the calcium diastolic release and promoting cardiac arrhythmias by 
delayed after depolarizations (Marx SO, 2000). Indeed, these authors showed that the 
presence of different CPVT mutations decreases the affinity of FKBP12.6 binding to RyR, 
leading to calcium leak (Marx SO, 2000; Wehrens et al., 2003; Lehnart et al., 2008)}. However, 
these findings have not been confirmed by others groups (Tiso et al., 2002; George et al., 
2003; Liu et al., 2006; Xiao et al., 2007; Guo et al., 2010). 
 
Fig. 2. Triggered activity observed in RyR2R4496C myocytes. 3D line-scan images of 
ventricular myocytes isolated from (A) a wild type mouse and (B) RyRR4496C mouse during 
electrical stimulation (4Hz). RyRR4496C cell shows Ca2+-waves that induce consistent with 
DADs. Finally Matsusaki’s group has described altered interdomain RyR2 interactions in 
CPVT (Ikemoto & Yamamoto, 2000; Tateishi et al., 2009). They proposed that under 
physiological conditions, N and central terminal domains of RyR2 interact, maintaining the 
channel closed. CPVT-linked mutations in the N or central domain, causing a disruption of 
the interaction (domain unzipping), rendering the channel more sensitive to changes in 
luminal or cytosolic calcium. So, it is reasonable to hypothesize that mutations in these 
regions of RyR2 could affect the physiological conformational states, resulting in channel 
dysfunction, as occurs in CPVT (Lobo & Van Petegem, 2009; Tung et al., 2010). 
On the other hand, our group using a knock-in mice model that express R4496C mutation in 
the cardiac RyR2 (the equivalent mutation found in CPVT patients, R4497C) demonstrated 
an enhanced of Ca2+ sensitivity of the mutant RyR2 (Fernandez-Velasco et al., 2009). This 
mice model mimics extraordinarily the clinical manifestations of patients presenting the 
RyR2R4497C mutation, including the bidirectional VT. RyR2R4496C cardiomyocytes 
exposed to adrenaline and caffeine developed DADs, suggesting that triggered arrhythmias 
are elicited by adrenergic activation (Nakajima et al., 1997; Liu et al., 2006). We demonstrated 
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that untreated RyR2R4496C myocytes have increased spontaneous Ca2+ release in diastole 
during electrical pacing, due to the enhanced Ca2+ sensitivity of mutant RyR2; this 
abnormality is further augmented by exposure to isoproterenol and increasing pacing rates 
(Figure 2). 
4.4 Mutations in calsequestrin 2 linked to CPVT 
As previously mentioned, alterations in the control of Ca2+ release by changes in luminal 
calcium can induce serious disruptions in the Ca2+ cycling. This is what happens in the 
recessive form of CPVT associated with mutations in calsequestrin (CASQ2) (Eldar et al., 
2003). CASQ2 is a polymer with a low-affinity and high capacity of calcium binding located 
in the luminal side of SR (Beard et al., 2004; Gyorke & Terentyev, 2008). Although it is 
documented that CASQ2 interacts with RyR2 via triadin and junctin, and acts as luminal 
calcium sensor by inhibiting RyR2 function at low luminal calcium concentration (Gyorke et 
al., 2004; Terentyev et al., 2007), the exact mechanism by which this protein exerts their 
function is not completely understood. 
To date, 12 CASQ2-mutations and 3 non synonymous polymorphisms have been detected in 
CPVT subjects (http://www.fsm.it/cardmoc/). Although some of these mutations affect the 
protein synthesis, reducing significantly the CASQ2 expression in the heart, others induce a 
defective protein expression and alter the ability of SR calcium buffering (Postma et al., 2002; 
Terentyev et al., 2003; di Barletta et al., 2006; Knollmann et al., 2006; Terentyev et al., 2006). 
Related to this, different authors have shown in murine cardiomyocytes and in heterologous 
systems, that mutants of CASQ2 including CASQ2 (L167H), CASQ2 (G112+5X), CASQ2 
(R33Q), CASQ2-/- and CASQ2 (D307H) induce a deregulation of SR Ca2+ release, leading to 
arrhythmogenic DADs (Lahat et al., 2001a; Lahat et al., 2001b; Terentyev et al., 2003; di 
Barletta et al., 2006; Knollmann et al., 2006; Terentyev et al., 2006; Dirksen et al., 2007). These 
observations are consistent with the ECG pattern observed in CPVT patients (Napolitano & 
Priori, 2007). 
Missense and nonsense CASQ2 mutations have been reported. Regarding missense 
mutations, CASQ2 (D307H), CASQ2 (R33Q) and CASQ2 (L67H) have been found in CPVT 
subjects (Terentyev et al., 2006; Kim et al., 2007; Qin et al., 2008; Terentyev et al., 2008). These 
mutations alter the CASQ2 interaction with RyR2, compromising its ability to store Ca2+ in 
the SR. So far, it has been reported that there are four nonsense mutations that cause the 
protein to be reduced or deleted (di Barletta et al., 2006). In vivo, CASQ2-/- mice exhibit 
CPVT with a bidirectional QRS pattern, the classic ECG feature observed in their human 
disease (Knollmann et al., 2006). 
Cellular arrhythmias were detected in cardiomyocytes expressing CASQ2 mutants under β-
adrenergic stimulation (Terentyev et al., 2003; di Barletta et al., 2006; Dirksen et al., 2007). 
These results are consistent with the arrhythmogenic storm elicited by the emotional or 
physical stress in CPVT patients. 
Because there is a correlation between the spontaneous Ca2+ release and the DADs, the 
question is why the spontaneous calcium release occurs. Different approaches address that 
mutations in CASQ2 compromise the two principal functions described for this protein: as a 
SR Ca2+ storage site and as modulator of RyR2 activity (Kubalova et al., 2005; Terentyev et 
al., 2006; Terentyev et al., 2008; Knollmann, 2009). Both mechanisms elicited an abnormal 
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control of RyR2 by luminal Ca2+ required to effective termination of SR Ca2+ release, 
promoting the spontaneous Ca2+ release during diastole. Studies using transgenic CPVT 
mice models with CASQ2 mutations confirm that the underlying mechanism of ventricular 
arrhythmias are DADs caused by spontaneous Ca2+ release under adrenergic stress 
(Mohamed et al., 2007). However, it is important to note that compensatory changes 
observed in the CASQ2 transgenic mice can alter the junctin and/or triadin function and 
may affect the manifestation of CPVT under chronic procedures. (Knollmann et al., 2006; 
Song et al., 2007). 
5. Supraventricular arrhythmias in CPVT 
CPVT patients often develop supraventricular arrhythmias as resting bradycardia and His-
Purkinje block (Sumitomo et al., 2003; Cerrone M, 2007; Sumitomo et al., 2007; Kazemian P, 
2011; Sy RW, 2011). Supraventricular arrhythmias (SVAs) are an important issue to 
underline during following-up patients with CPVT. Although the risk for SCD in CPVT 
patients is expected to be associated with ventricular arrhythmias, supraventricular 
abnormalities as sinus node dysfunction, atrioventricular block and supraventricular 
tachyarrhythmias result in significant increase of morbidity. Moreover, the frequent 
association of supraventricular arrhythmias in CPVT patients, which has been reported to 
precede or coexist with ventricular tachycardia, suggests that SVAs may be an important 
risk factor for SCD in this patient population (Sumitomo et al., 2007; Sy RW, 2011). These 
SVAs in single point mutations of RyR2 are usually bradycardia, atrial tachycardia, atrial 
fibrillation and atrioventricular reentry (Sumitomo et al., 2003; Sumitomo et al., 2007; 
Kazemian P, 2011; Sy RW, 2011). Additionally, Bhuiyan and coworkers found CPVT 
patients from 2 unlinked families with a deletion of 35 peptides in RyR2 exon-3, who 
presented also SVAs (sinus bradycardia, sinus block or arrest, atrioventricular block, atrial 
fibrillation and atrial standstill). Interestingly, these patients also presented left ventricular 
dysfunction and dilatation, which are rare in CPVT patients. 
Additionally, prevention of SVAs is also important in CPVT disease due to potential 
complications with implantable cardioverter- defibrillators (ICD) therapy. In CPVT, beta-
blockers are recommended, together with exercise restraint. Despite beta-blocker therapy, 
ICD are implanted in patients with previous cardiac arrest, or with recurrent syncope or 
documented ventricular tachycardia. However, SVAs are not benign arrhythmias in patients 
with CPVT; they potentially can trigger fast ventricular tachycardias and inappropriate ICD 
discharges that may lead to fatal ventricular arrhythmias (Pizzale et al., 2008). In the study 
by Sy and co-workers (Sy RW, 2011), one patient died of refractory ventricular 
tachycardia/ventricular fibrillation caused by inappropriate ICD shocks of rapidly 
conducting atrial fibrillation. 
The cellular mechanism of sinus bradycardia in CPVT is still unexplored. One possibility is 
that the function of one or several ion channels that participate in the Ca2+ clock mechanism 
is altered (i.e. NCX, L-type Ca2+ channel, etc.) and this abnormality may correspond to a 
Ca2+ and voltage clock uncoupling. It has been reported that the CPVT-linked mutation 
R4496C presents an increased “SR Ca2+ leak” in ventricular myocytes isolated from a 
transgenic mice (Fernandez-Velasco et al., 2009). A combined genetic and functional 
approach would be highly required to explore the involvement of RyR mutations on 
bradycardia and sino-atrial node dysfunction in CPVT disease. 
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6. Purkinje conduction system 
The His-Purkinje system is responsible of the propagation for the action potential to the 
ventricles. The electrical properties of Purkinje cells are different from those of nodal cells, 
because they displayed low pacemaker activity and even slower conduction rate. However, 
Purkinje cells exhibit long action potential duration (APD) and therefore they are prone to 
EAD and DAD formation (Makarand Deo, 2010). This long APD provides sufficient time for 
L-type calcium channel reactivation, leading to EAD or DAD formation, which can lead to 
ectopic beats. Although EADs formation in Purkinje fibers has been quite explored (Fedida 
D, 2006), little is known concerning the development of DADs in these cardiac conducting 
fibers (GR., 1980; Gough WB, 1989). It has been recently described that DADs are associated 
to the development of CPVT disease (Liu et al., 2006; Fernandez-Velasco et al., 2009), but the 
mechanism of how DADs induce bidirectional VT is unknown. To fulfill this question, 
Cerrone and co-workers performed whole-heart optical mapping in heart isolated from 
knock-in mice carrying the R4496C mutation, and they found that bidirectional VT was 
caused by two foci in the distal His-Purkinje system, one in the right ventricle and the other 
in the left ventricle, activating the ventricles alternatively (Cerrone M, 2007). Polymorphic 
VT was initially multifocal but eventually became reentrant and degenerated into 
ventricular fibrillation. Moreover, chemical ablation of the right ventricular His-Purkinje 
system with Lugol solution converted bidirectional VT to monomorphic VT in mice. The 
same group further demonstrated in an additional report that Purkinje cells are more 
sensitive to the R4496C RyR2 mutation than ventricular myocytes, which strongly supports 
the idea that Purkinje cells are responsible of the arrhythmia in CPVT (Herron TJ, 2010). The 
latter result was further explored by other work, which has also tested that Flecainide 
reduce spontaneous Ca2+ release in Purkinje cells (Kang G, 2010). 
6.1 Treatment of CPVT 
Although β-adrenergic blockers is the most common treatment chosen for CPVT patients, 
they are incompletely effective with up to 30% of subjects requiring implantable 
cardioverter-defibrilators (ICDs) (Priori et al., 2002). In severe cases of CPVT, the 
nondihydropyridine Ca2+ channels blockers may also be effective (Swan et al., 2005; Rosso et 
al., 2007). 
Dantrolene, a drug used to prevent malignant hyperthermia in patients with mutations in 
RyR1 who have been exposed to volatile anaesthetics, has been proposed to have 
therapeutic potential in heart disease by causing “rezipping” of the amino and central 
domains of RyR2 (Kobayashi et al., 2009; Kobayashi et al., 2010). 
More recently, a protective effect of flecainide was proposed for CPVT treatment, thus this 
drug is able to block Ca2+ leak from RyR2 in CASQ2 deficient mice (Watanabe et al., 2009). 
Finally, the use of drugs (JTV519) with selective action on FKBP 12.6 is still remaining in 
discrepancy, because diverging data to this respect were obtained. 
7. Arrhythmogenic right ventricular dysplasia 
Arrhythmogenic right ventricular dysplasia (ARVD) is a genetic form of cardiomyopathy 
that by contrast to CPVT, primarily affects the right ventricle (RV) and is characterized by 
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the abnormal replacement of myocytes by adipose and fibrous tissue (Basso et al., 2009). The 
estimated prevalence of ARVD in general population ranges from 1 in 2000 to 1 in 5000 
(Corrado et al., 1997) and is more frequent in men than in women, being a major cause of 
sudden death in the young and in athletes. 
ARVD was initially believed to be a developmental defect of the RV myocardium, leading to 
the original designation of dysplasia (Basso et al., 1996). The diagnostic of ARVD patients 
including MRI, echocardiography, electrocardiography and right ventricle biopsy (McKenna et 
al., 1994). ARVD is characterized by functional abnormalities of the right ventricle, with 
abnormal depolarization/repolarization, leading to syncope, ventricular arrhythmias and 
sudden death (Rossi et al., 1982). Interestingly, in a high percent of patients left ventricular 
dysfunction was found (Corrado et al., 1997).The most typical clinical presentation of ARVD is 
symptomatic ventricular arrhythmias of right ventricular origin, usually triggered by effort. 
ARVD can be inherited as an autosomal dominant disease with reduced penetrance and 
variable expression, although autosomal recessive forms also have been detected 
(Rampazzo et al., 2002). Mutations in genes encoding for different molecules have been 
linked to ARVD. To this regard, mutations in adhesion proteins (plakoglobin, desmoplakin, 
plakophilin-2 and desmoglein-2), in cytokines (Transforming grow factor beta 3), in 
transmembrane protein 43 and in RyR2 have been detected in ARVD subjects (Tiso et al., 
2001; Rampazzo et al., 2002; Gerull et al., 2004; Beffagna et al., 2005; Pilichou et al., 2006; 
Merner et al., 2008). 
Regarding RyR2 mutations, ARVD patients with mutations in RyR2 tend to have mild 
ARVD symptoms and are classified as ARVD2. The R176Q mutation has been associated 
with the ARVD disease and also carries out a second mutation of T2504M (Tiso et al., 2001). 
Both mutations induced the increased RyR activity in vitro (Thomas et al., 2004). 
The mice model that harbors R176Q mutation allowed for the better understanding of this 
arrhythmogenic disease. Hearts from R176Q heterozygous mice were structurally normal, 
but under β-adrenergic stimulation, myocytes elicited oscillatory Ca2+ signals, leading to 
mice VT (Kannankeril et al., 2006). 
7.1 Treatment of ARVD 
There is not a curative treatment, instead, the aim is to detect patients with high risk and 
prevent complications. 
The four therapeutic options are pharmacological agents (first choice), catheter ablation (if 
the patient is refractory to drug treatment or the disease is localized), implantable 
cardioverter-defibrillators (in refractory subject at risk for sudden death) and surgery as the 
last option (ventriculotomy and disconnection of the RV free wall) or cardiac transplantation 
(if severe terminal heart failure) (McKenna et al., 1994). 
As we mentioned, the first option for ARVD patients is the pharmacological treatment, 
including ACEI, anticoagulants, antiarrhythmic agents as sotalol, verapamil, beta-blockers, 
amiodarone and flecainide. 
In conclusion, genetic analysis is essential in both CPVT and ARVD patients, because if a 
pathogenic mutation is identified, a pre-symptomatic diagnosis of the disease among family 
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members might be provided and also the development of the disease can be monitored to 
assess the risk of transmitting them offspring. 
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